Snowflake Is Up 21%. The Growth Rate Says Keep Going.
Three straight quarters of accelerating product revenue and raised guidance make a credible case that the move is not over.
Three straight quarters of accelerating product revenue and raised guidance make a credible case that the move is not over.
September 3, 2026 After the FDA reversed course, a small biotech got a green light...
With crude back above $90 and core PCE still running at 3.3%, the Beige Book is the last qualitative test…